四環醫藥(00460.HK):SGLT-2抑制劑創新藥脯氨酸加格列淨片獲國家藥監局批准上市
格隆匯1月23日丨四環醫藥(00460.HK)發佈公吿,集團旗下非全資附屬公司惠升生物製藥股份有限公司(“惠升生物”)研發的鈉-葡萄糖轉運蛋白2抑制劑(“SGLT-2抑制劑”)、國家1類創新藥脯氨酸加格列淨片(商品名:惠優靜®“,加格列淨”)獲中國國家藥品監督管理局(“國家藥監局”)上市批准,用於治療2型糖尿病。這是國內第二個獲批上市的自主研發的SGLT-2抑制劑創新藥,標誌着惠升生物在糖尿病治療領域創新藥研發方面取得了突破性進展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.